Several changes to scientific culture and policy are needed to aid the identification of new drug targets and therapies for central nervous system disorders from the rapidly growing volume of 'big' data in neuroscience.
This is a preview of subscription content, log in via an institution to check access.
Change history
01 September 2014
The middle initial of the second author was incorrect; it should be Thomas R. Insel, as above. The online versions have been corrected accordingly.
References
Shen, L., et al. Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging Behav. 8, 183–207 (2014).
Chiang, M. C. et al. Gene network effects on brain microstructure and intellectual performance identified in 472 twins. J. Neurosci. 32, 8732–8745 (2012).
Denny, J. C. et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nature Biotech. 31, 1102–1110 (2013).
Samtani, M. N. et al. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J. Clin. Pharmacol. 52, 629–644 (2012).
Yuan, L. et al. Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. Neuroimage 61, 622–632 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Manji, H., Insel, T. & Narayan, V. Harnessing the informatics revolution for neuroscience drug R&D. Nat Rev Drug Discov 13, 561–562 (2014). https://doi.org/10.1038/nrd4395
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4395
- Springer Nature Limited
This article is cited by
-
Erratum: Harnessing the informatics revolution for neuroscience drug R&D
Nature Reviews Drug Discovery (2014)